Abstract
Increasing evidence suggests that abnormalities in amino neurotransmission are associated with the neurobiology of depression. Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function. In humans, depressed patients have lower plasma, CSF and brain GABA concentrations than non-depressed comparison subjects. The recent discovery that several anticonvulsant and GABA-mimetic agents possess mood stabilizing and antidepressant properties has further increased interest in these findings. This review outlines the existing literature investigating the possible involvement of GABA in the neurobiology of depression and briefly highlights how this information may afford new targets for antidepressant drug development.
Keywords: Psychiatry, mood disorders, pathophysiology, GABA, neurosteroid
CNS & Neurological Disorders - Drug Targets
Title: GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action
Volume: 6 Issue: 2
Author(s): Gerard Sanacora and Aybala Saricicek
Affiliation:
Keywords: Psychiatry, mood disorders, pathophysiology, GABA, neurosteroid
Abstract: Increasing evidence suggests that abnormalities in amino neurotransmission are associated with the neurobiology of depression. Preclinical studies demonstrate that GABA modulating agents are active in commonly used rodent behavioral models of antidepressant activity, and that chronic administration of antidepressant drugs induces marked changes in GABAergic function. In humans, depressed patients have lower plasma, CSF and brain GABA concentrations than non-depressed comparison subjects. The recent discovery that several anticonvulsant and GABA-mimetic agents possess mood stabilizing and antidepressant properties has further increased interest in these findings. This review outlines the existing literature investigating the possible involvement of GABA in the neurobiology of depression and briefly highlights how this information may afford new targets for antidepressant drug development.
Export Options
About this article
Cite this article as:
Sanacora Gerard and Saricicek Aybala, GABAergic Contributions to the Pathophysiology of Depression and the Mechanism of Antidepressant Action, CNS & Neurological Disorders - Drug Targets 2007; 6 (2) . https://dx.doi.org/10.2174/187152707780363294
DOI https://dx.doi.org/10.2174/187152707780363294 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Organoids as <i>Ex Vivo</i> Culture System to Investigate Infection-host Interaction in Gastric Pre-carcinogenesis
Recent Advances in Inflammation & Allergy Drug Discovery Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry The Hippocampal Autophagic Machinery is Depressed in the Absence of the Circadian Clock Protein PER1 that may Lead to Vulnerability During Cerebral Ischemia
Current Neurovascular Research Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Synthesis and Medicinal Applications of Benzimidazoles: An Overview
Current Organic Synthesis Membrane Domains as Signaling Centers in Macrophages and T-Cells: From Concepts to Experiments
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Membrane Interactive α-Helices in GPCRs as a Novel Drug Target
Current Protein & Peptide Science Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Role of Nitrosative Stress and Activation of Poly(ADP-ribose) Polymerase-1 in Cardiovascular Failure Associated with Septic and Hemorrhagic Shock
Current Vascular Pharmacology